万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://journals.lww.com/cardiovascularpharm/pages/default.aspx
3、投稿网址：http://www.editorialmanager.com/jcvp/
4、官网邮箱：Emily.hurd@wolterskluwer.com
5、期刊刊期：月刊，一年出版12期。
2021年7月15日星期四
投稿须知【官网信息】
Instructions for Authors
SCOPE
Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias.
Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.
As biological sex influences the prevalence, morbidity and mortality associated with these conditions, and as sex influences drug metabolism and efficacy, the Journal requires that the sex of the experimental material (cells, tissues, animals) and human participants be identified in all articles. In experiments where both male and female are identified, data should be reported by sex even if the study was not powered to identify a sex difference.
Ethical/Legal Considerations
A submitted manuscript must be an original contribution not previously published (except as an abstract or a preliminary report), must not be under consideration for publication elsewhere, and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of Lippincott Williams & Wilkins. In keeping with this requirement, every manuscript submitted will be analyzed by plagiarism detection software. In cases where significant repetition of previously published material is detected, the manuscript will be rejected without review. Each person listed as an author is expected to have participated in the study to a significant extent. Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the publisher.
Posting an un-refereed manuscript to a pre-print server is not considered prior publication as long as the following conditions are met:
Pre-print server deposition must be acknowledged during submission and any DOIs or associated accession numbers provided.
Alterations of a manuscript that are based on the peer review process may not be deposited.
The pre-print version cannot be indexed in MEDLINE or PubMed.
Upon publication, the archived pre-print must be updated by the authors with a DOI and link to the published version of the article.
Conflict of Interest Disclosure:
A DESCRIPTION OF ANY CONFLICT OF INTEREST FOR ALL OF THE AUTHORS MUST BE PROVIDED on the title page. The journal also requires authors to identify any financial interests or affiliations with institutions, organizations, or companies that are mentioned in the manuscript or whose products or services are discussed. The Conflict of Interest Disclosure statement will be included in the published article.
Declaration of Funding Source:
ACKNOWLEDGMENT OF GRANTS OR FINANCIAL SUPPORT MUST BE DECLARED. Authors of all articles in which the effect of a drug, appliance, or treatment is evaluated must also acknowledge all support from the manufacturer of such drug, appliance, or treatment or its competitor. Authors of review articles, editorials, letters to the editor, and other commentaries must disclose any financial interests that might have an impact on the views expressed in the article, editorial, letter, or commentary. The Declaration of Funding Source statement will be included in the published article.
The conflict of interest disclosure and funding declaration must be included on the title page of the manuscript and in Editorial Manager. Authors with nothing to declare should provide a statement to that effect. Manuscripts submitted without the required disclosures will be returned to the authors.
Patient Anonymity and Informed Consent
It is the author's responsibility to ensure that a patient's anonymity be carefully protected and to verify that any experimental investigation with human subjects reported in the manuscript was performed with informed consent and following all the guidelines for experimental investigation with human subjects required by the institution(s) with which all the authors are affiliated. Authors should remove patients' names and other identifying information from figures. If any identifying details appear in text, tables, and/or figures, the author must provide proof of informed consent obtained from the patient (i.e., a signed permissions form). Photographs with bars placed over eyes of patients should NOT be used in publication. If they are used, permission from the patient is required.
Use of Experimental Animals
It is the author’s responsibility to provide evidence that all studies on experimental animals have been conducted under protocols reviewed and approved by the author’s institutional animal care and use committee and to adhere to generally accepted international guidelines for animal experimentation.
Copyright
In addition, each author must complete and submit the journal's copyright transfer agreement, which includes a section on the disclosure of potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (www.icmje.org/update.html).
A copy of the form is made available to the submitting author within the Editorial Manager submission process. Co-authors will automatically receive an Email with instructions on completing the form upon submission.
Compliance with NIH and Other Research Funding Agency Public Access Requirements
A number of research funding agencies require or request authors to submit the post-print (the article after peer review and acceptance but not the final published article) to a repository that is accessible online by all without charge. As a service to our authors, WK will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the National Institutes of Health, Wellcome Trust, or Howard Hughes Medical Institute, to PubMed Central. Authors may indicate such funding when completing the Copyright Transfer Agreement.
Open access
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. Authors may take advantage of the open access option at the point of acceptance to ensure that this choice has no influence on the peer review and acceptance process. These articles are subject to the journal's standard peer-review process and will be accepted or rejected based on their own merit.
Open access articles will incur an article processing charge (APC), which is charged on acceptance of the article and should be paid within 30 days by the author, funding agency or institution. Payment must be processed for the article to be published open access. For a list of journals and pricing please visit our Wolters Kluwer Open Health Journals page.
Authors retain copyright
Authors retain their copyright for all articles they opt to publish open access. Authors grant Wolters Kluwer an exclusive license to publish the article and the article is made available under the terms of a Creative Commons user license. Please visit our Open Access Publication Process page for more information.
Creative Commons license
Open access articles are freely available to read, download and share from the time of publication under the terms of the Creative Commons License Attribution-NonCommerical No Derivative (CC BY-NC-ND) license. This license does not permit reuse for any commercial purposes nor does it cover the reuse or modification of individual elements of the work (such as figures, tables, etc.) in the creation of derivative works without specific permission.
Compliance with funder mandated open access policies
An author whose work is funded by an organization that mandates the use of the Creative Commons Attribution (CC BY) license is able to meet that requirement through the available open access license for approved funders. Information about the approved funders can be found here: http://www.wkopenhealth.com/inst-fund.php
FAQ for open access
http://www.wkopenhealth.com/openaccessfaq.php
Permissions
Authors must submit written permission from the copyright owner (usually the publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along with complete details about the source. Any permissions fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material, not the responsibility of Lippincott Williams & Wilkins.
PREPARATION OF MANUSCRIPT
Manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.
Note: Manuscripts submitted in less-than-acceptable English will not be sent for review and will be rejected. Therefore, those authors who are not fluent in English are strongly advised to have their manuscript reviewed and if necessary rewritten by an individual having fluency in the English language.
Manuscript Evaluation
Prior to submitting, we recommend that you run your manuscript through the Paperpal Preflight service, which instantly checks manuscripts for the most common errors in language and technical compliance. For more information on Paperpal, click here.
Manuscript Submission
Authors are required to submit their manuscripts via Editorial Manager http://www.editorialmanager.com/jcvp, a web-based tracking system. The site contains instructions on how to use the system, guidance on the creation of electronic art, and supporting documentation. In addition to serving as a submission platform, the site allows authors to follow the progression of their manuscript through the peer review process.
For questions about the manuscript submission process, please contact the Editorial Coordinator, Emily Hurd Emily.hurd@wolterskluwer.com
Section Categories
Manuscripts will be assigned to one of two section categories: Vascular or Cardiac.
For all manuscripts relating to vascular smooth muscle (including coronary), endothelium (including coronary), hypertension, vascular disease (including atherosclerosis), thrombosis and antithrombotic drugs, microcirculation, and hypolipidemic drugs please select ‘Vascular’ in the section/category box in Editorial Manager
For all submissions relating to cardiac muscle (including contraction and electrophysiology), cardiac ischemia, cardiac failure, cardiac surgery, studies of multiple tissues in which heart is included, and pharmacokinetics please select ‘Cardiac’ in the section/category box in Editorial Manager.
Reviewers
Authors should submit the names of reviewers from outside their home institution that they would recommend as well as those they believe should be disqualified from reviewing their submission. In the latter event, a statement of the basis for disqualification should be included. These names should be submitted in the SUGGEST REVIEWERS section in Editorial Manager. The suggested names will not be transmitted to the reviewers selected by the Editors. Under no circumstances should names of recommended or disqualified reviewers be included in the authors' letter of submission or in the body of the manuscript.
Article Types
Original articles
Original articles on new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, and clinical results with new and established agents are considered. Subject matter includes traditional pharmacologic agents, naturally occurring compounds and genetically manipulated constructs, including those used in gene and cell therapy.
Clinical Trials
Clinical trials prospectively assign human subjects to specific intervention or comparison groups and determine relationships between a pharmacologically-based intervention and outcome. To ensure consistency with the guidelines of the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (http://content.nejm.org/cgi/content/full/NEJMe078110), all trials submitted to the Journal with patient enrollment commencing after January 1, 2008 must be registered in a public trials registry. The registry must incorporate free public access, and must be searchable, open to prospective registrants, and have not-for-profit management. The following information must be included in the registry: (1) unique identifying number, (2) statement of intervention(s), (3) hypothesis, definition of primary and secondary outcome measurements, eligibility criteria, target number of subjects, funding source, contact information for principal investigator, and dates of registration, start and completion. Authors should provide the URL and trial identification number on the title page of the manuscript. This information will be published with the article. Clinical trial reports should also comply with the Consolidated Standards of Reporting Trials (CONSORT) (http://www.consort-statement.org/). The CONSORT statement should be used to guide the preparation of manuscripts reporting the results of randomized controlled trials. Observational studies should adhere to the guidelines published by the STROBE group (http://www.strobe-statement.org/). A flow diagram detailing enrolment, intervention allocation, follow-up, and data analysis with number of subjects at each point should be included for all clinical studies.
Drugs in the Pipeline (Drug Discovery)
Drug Discovery articles deal with various aspects of drug design, development, and discovery process. These articles may focus on a particular cardiovascular disease or health challenge, and the status of drug development to address the shortcomings of current therapies. Generally, these articles are focused more on basic science and recent cellular, molecular, and genetic developments from a pharmacological perspective. Drug Discovery articles cover as well, new developments in drug design and discovery, such as data mining, small molecule drug screening libraries, and legal and economic issues.
Note: All Drugs in the Pipeline submissions must include text boxes, which highlight the important points of the article for easy reference. A separate list of numbered text boxes must be uploaded with manuscripts. Authors must indicate in the text where boxes are best placed.
Emerging Concepts in Pharmacotherapeutics
Emerging Concepts in Pharmacotherapeutics deals with high quality review articles describing emerging areas in cardiovascular pharmacology. The purpose of this section is to provide readers with an in-depth understanding of the pharmacology, available and ongoing clinical trial data, and potential clinical role of emerging therapies for cardiovascular (and related) diseases. These reviews should not exceed 10,000 words, 150 references, and 5 figures/tables. While these articles are invitation only, interested authors can submit ideas for reviews to the Section Editor. Authors may also submit original research articles related to emerging drug therapies with the Section Editor's approval.
……
更多详情：
http://edmgr.ovid.com/jcvp/accounts/ifauth.htm
